Loading articles...
Colorectal NeoplasmsCMS Adopts Performance-Based Standards for CRC Biomarker Tests
The Centers for Medicare & Medicaid Services (CMS) has implemented new performance-based standards for colorectal cancer (CRC) biomarker tests, despite ongoing questions regarding the clinical utility of some assays.
Renal Cell CarcinomaBelzutifan Plus Pembrolizumab Approved for Adjuvant RCC
The FDA has approved belzutifan plus pembrolizumab for adjuvant renal cell carcinoma, offering a new option for patients at high risk of recurrence.
Solid TumorsMesothelioma Survival Challenges Persist in the US
Despite advances in oncology, mesothelioma survival rates in the US remain low, highlighting persistent challenges in early diagnosis and effective treatment.
Brain NeoplasmsctDNA Predicts Relapse in Early Cancer, but Clinical Action Remains Unclear
Circulating tumour DNA (ctDNA) detection post-surgery predicts relapse in early-stage cancer, but evidence for adjuvant therapy escalation based solely on ctDNA is lacking.
Prostatic NeoplasmsPROTEUS Trial: Neoadjuvant Apalutamide Plus ADT in High-Risk Prostate Cancer
The PROTEUS trial investigated neoadjuvant apalutamide plus ADT for high-risk localised prostate cancer, showing improved pathologic complete response rates.
MelanomaCAR-T Therapy Versus Bispecific Antibodies
The next phase of CAR-T addresses its biggest limitations: off-the-shelf allogeneic products, in vivo gene delivery, and bispecific antibodies that redirect T cells without any gene engineering. Sarah Mitchell and James Carter explore where the technology i...
MelanomaSmall Molecules VS CAR-T In CLL
By the time CAR-T arrived in CLL, the disease had already been transformed by BTK inhibitors and venetoclax. TRANSCEND CLL 004 showed 18% CR in BTKi/venetoclax-refractory disease. Sarah Mitchell and James Carter explore why CLL is harder for CAR-T, where it...
MelanomaMoving CAR-T To Earlier Myeloma Lines
Ciltacabtagene autoleucel achieved a 97% overall response rate and 67% complete response in triple-class refractory multiple myeloma - numbers not thought achievable a decade ago. CARTITUDE-4 has now moved it to the second line. Sarah Mitchell and James Car...
Solid TumorsCAR-T Masterstroke Or Biological Chaos?
In 2012, a 6-year-old with relapsed ALL became the first child successfully treated with CAR-T cell therapy. That case launched a revolution. Sarah Mitchell and James Carter explain how chimeric antigen receptor T cells are engineered, why CD19 was the firs...
Solid TumorsDoctor-Patient Communication Improves Treatment Acceptance in Cancer
Effective doctor-patient communication, focusing on patient self-blame, significantly increases treatment acceptance rates in cancer patients.